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Objectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous 
  immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many 
European countries. The clinical efficacy of SLIT has been established in a number of clinical 
trials and meta-analyses. However, because SLIT is self-administered by patients without medical 
supervision, the degree of patient adherence with treatment is still a concern. The objective of 
this study was to evaluate the perception by allergists of issues related to SLIT adherence.
Methods: We performed a questionnaire-based survey of 296 Italian allergists, based on the 
adherence issues known from previous studies. The perception of importance of each item was 
assessed by a VAS scale ranging from 0 to 10.
Results: Patient perception of clinical efficacy was considered the most important factor 
(ranked 1 by 54% of allergists), followed by the possibility of reimbursement (ranked 1 by 34%), 
and by the absence of side effects (ranked 1 by 21%). Patient education, regular follow-up, and 
ease of use of SLIT were ranked first by less than 20% of allergists.
Conclusion: These findings indicate that clinical efficacy, cost, and side effects are perceived as 
the major issues influencing patient adherence to SLIT, and that further improvement of adher-
ence is likely to be achieved by improving the patient information provided by prescribers.
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Background
Sublingual immunotherapy (SLIT) is currently accepted as a viable alternative to sub-
cutaneous immunotherapy (SCIT) to treat allergic rhinitis and asthma,1 and is widely 
used in clinical practice in many European countries. The clinical efficacy of SLIT has 
been established in a number of clinical trials and meta-analyses,2 and its safety profile 
has been reported to be satisfactory in adults and children using high allergen doses.3 
However, because SLIT is self-administered by patients without medical supervision, 
assessment of adherence to treatment is still a concern, although the advantage of home 
administration does remove one of the main causes for no adherence, ie, the need to 
go to a physician’s office for treatment, which was previously the case with SCIT.4 
The first studies of SCIT in the 1990s reported an adherence rate of about 50%, with 
better rates (up to 75%) subsequently found using less demanding injection schedules.4 
With SLIT, higher adherence rates of up to 90% have been described.4
Adherence is commonly defined as the extent to which the patient’s behavior matches 
the treatment recommendations from the prescriber5 and is essential for the success of 
any medical treatment, especially for chronic diseases, such as rhinitis and asthma. Medi-
cation intake can be assessed using several direct or indirect methods. Direct methods, Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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which measure the concentration of a   specific drug in blood 
or urine, cannot be used for assessment of SLIT adherence. 
Indirect methods require periodic counting of leftover doses 
or use of questionnaires in which patients report the amount 
and frequency of drug intake. Considering the recent literature, 
adherence to SLIT in clinical trials and postmarketing surveys 
would appear overall to be satisfactory, ranging from 75% to 
90%,6–8 with inconvenience and cost of treatment being the 
main causes for nonadherence. All these studies focused on 
patients, but the role of physicians must not be overlooked, 
because their attitude towards a treatment influences the infor-
mation they provide to patients when prescribing SLIT in their 
everyday clinical practice which, in turn, may influence patient 
adherence. For example, insufficient information on the com-
mon side effects of SLIT, such as local reactions in the mouth, 
may lead to unnecessary treatment modification and even to 
withdrawal.9 The present questionnaire-based survey sought 
the opinions of Italian allergists on SLIT adherence.
Methods
A multiple-choice questionnaire was administered to 325 
Italian allergy specialists, randomly selected from a national 
list, who commonly recommend treatment with SLIT. The 
questionnaire comprised 10 questions concerning different 
factors which can favorably influence patient adherence with 
SLIT. These factors were perceived efficacy, tolerability, 
cost reimbursement, administration regimen (pre-coseasonal/
continuous), ease of administration, regular contact with the 
patient, approval of the treatment by the general practitio-
ner, patient education, and follow-up visits. The allergist’s 
perception of the proportion of patients completing the 
recommended SLIT duration of three years was used to 
estimate the extent of follow-up.1 Each question was to be 
answered using a 10cm visual analog scale (VAS) ranging 
from 1 (“extremely important”) to 10 (“of no relevance”). 
The VAS is recognized as a very useful tool for detecting 
an individual’s perception of a specific medical issue.10 The 
physicians were also asked to choose the most relevant factor 
that, in their opinion, impaired adherence.
Results
Of the 325 allergy specialists contacted, 296 (91%) returned 
a valid questionnaire with all questions answered. The mean 
age of the allergists was 51 years; 40.5% were female, and 
5% were in private practice, 60% in hospital practice, and 
35% worked in a territorial health care setting.
The patient’s perception of clinical efficacy was consid-
ered to be the most important factor influencing   adherence, 
and was ranked 1 (“extremely important”) by 54% of 
  allergists; this finding was further confirmed by considering 
the sum of the first three ranks (Tables 1 and 2), with 78.1% 
of allergists considering this to be the most important fac-
tor. The second important factor influencing adherence was 
considered to be the possibility of cost reimbursement by 
the National Health Service, with 34% of allergists ranking 
this first (Table 3). The absence of treatment side effects was 
considered to be the third important factor influencing adher-
ence, ranked first by 21.3% of allergists (Table 4).
The remaining factors ranked first in less than 20% of 
the answers. Patient education, acceptance by the general 
practitioner, and regular follow-up visits were not considered 
particularly relevant to maintenance of adherence. Also, the 
ease of administration of SLIT received low consideration 
by allergists. Considering the main causes of treatment 
discontinuation, the cost of SLIT was reported by 98% of 
physicians, followed by side effects (48%), and lack of per-
ceived clinical efficacy (42%).
When asked to define a method to increase patient adher-
ence, the majority (57.8%) of allergists chose telephone 
contact as a more useful tool than frequent follow-up visits. 
Finally, most allergists (57.8%) thought that a three-year 
course of SLIT would have an adherence of 50%–80%, while 
29.4% estimated adherence to be over 80%, and only 7.1% 
estimated adherence to be lower than 50% (Table 5).
Discussion
Adherence to the recommended therapeutic regimen is 
crucial in all aspects of medicine,11–13 especially in chronic 
diseases, such as rhinitis and asthma. This is particularly true 
with SLIT which is self-administered by patients at home and 
involves prolonged treatment without medical supervision, 
and the potential therefore exists for arbitrary modification 
of the dosing regimen, which can lead to a progressive 
Table 1 Percentage of allergists who ranked questionnaire issues 
influencing adherence to SLIT at 1–3
n %
Perceived efficacy of treatment by patients 231 78.1
Tolerability 196 66.2
cost reimbursement 171 57.8
Patient education 117 39.4
ease of use 106 35.7
regular physician-patient contact  95 32.1
regular follow-up visits 90 30.4
Administration regimen (pre-co seasonal) 72 24.3
Administration regimen (continuous) 65 21.9
Approval from general practitioner 49 16.6
Abbreviation: SLiT, sublingual immunotherapy.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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reduction of clinical efficacy and finally, discontinuation of 
treatment. A treatment duration of 3–5 years has been shown 
to be optimal for modifying the natural history of both house 
dust mite14,15 and pollen16 allergy. Patients embarking on SLIT 
should therefore aim for this treatment duration.
The present study investigated how specialists perceive 
SLIT adherence issues using a questionnaire canvassing 
factors that are commonly believed to affect compliance. 
As expected, the patients’ perceived clinical efficacy was 
the most relevant issue, and was even more important 
than the presence of side effects. It is worthy of note that 
perceived clinical efficacy may also have a negative effect, 
because the patient might feel that once the symptoms are 
controlled the treatment is no longer needed, which leads 
to premature cessation of treatment.16 This misconception 
could be addressed by patient education, as recommended in 
consensus documents for any level of severity of allergy.17 
By contrast, perhaps surprisingly, patient education (and 
parental education, when SLIT is administered children) and 
ease of administration were not judged by the allergists to be 
relevant issues. An accepted definition of patient education is 
“the process by which health professionals and others impart 
information to patients that will alter their health behaviours 
or improve their health status”.18 It was recently demonstrated 
that patients receiving an educational programme on SLIT 
showed better compliance than patients receiving standard 
verbal instructions.19
Because adherence is considered to be a dynamic process, 
patient perception of treatment efficacy should be regularly 
evaluated by the attending allergist. Moreover, before begin-
ning SLIT, physicians should give correct instructions and 
explanations to patients, especially concerning the treatment 
duration needed before assessing symptomatic relief, to avoid 
unrealistic expectations. The other two issues judged by the 
allergists to be important in compliance were tolerability 
and treatment cost. It is known that SLIT has a good safety 
profile, with local reactions in the mouth or gastrointestinal 
tract being the most common side effects,20 but generally 
these reactions are quite easy to manage and do not require 
Table 2 Allergists’ ranking of perception of efficacy as the most 
important factor in adherence to SLiT
Ranking n % CI 95%
Lower Upper
1 161 54.4 48.7 60.1
2 49 16.6 12.3 20.8
3 21 7.1 4.2 10.0
4 7 2.4 0.6 4.1
5 15 5.1 2.6 7.6
6 5 1.7 0.2 3.2
7 7 2.4 0.6 4.1
8 13 4.4 2.1 6.7
9 6 2.0 0.4 3.6
10 8 2.7 0.9 4.6
nD 4 1.4 0.0 2.7
Total 296
Abbreviations: SLIT, sublingual immunotherapy; CI, confidence interval; ND, not 
defined.
Table 3 ranking of cost reimbursement in adherence to SLiT
Ranking n % CI 95%
Lower Upper
1 102 34.5 29.0 39.9
2 32 10.8 7.3 14.3
3 37 12.5 8.7 16.3
4 26 8.8 5.6 12.0
5 19 6.4 3.6 9.2
6 12 4.1 1.8 6.3
7 16 5.4 2.8 8.0
8 20 6.8 3.9 9.6
9 11 3.7 1.6 5.9
10 16 5.4 2.8 8.0
nD 5 1.7 0.2 3.2
Total 296
Abbreviations: SLIT, sublingual immunotherapy; CI, confidence interval; ND, not 
defined.
Table 4 ranking of treatment tolerability in adherence to SLiT
Ranking n % 95% CI
Lower Upper
1 63 21.3 16.6 25.9
2 82 27.7 22.6 32.8
3 51 17.2 12.9 21.5
4 19 6.4 3.6 9.2
5 19 6.4 3.6 9.2
6 15 5.1 2.6 7.6
7 11 3.7 1.6 5.9
8 15 5.1 2.6 7.6
9 12 4.1 1.8 6.3
10 6 2.0 0.4 3.6
nD 3 1.0 -0.1 2.2
Total 296
Abbreviations: SLIT, sublingual immunotherapy; CI, confidence interval; ND, not 
defined.
Table 5 Three-year SLiT adherence as perceived by allergists
Adherence N % 95% CI
Lower Upper
.80% 87 29.4 24.2 34.6
80%–50% 171 57.8 49.3 66.3
,50% 21 7.1 1.2 13.0
nA 17 5.7 0.0 12.5
Total 296
Abbreviations: SLIT, sublingual immunotherapy; CI, confidence interval; NA, not 
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interruption of treatment.9 In this regard, patient education 
is likely to be a crucial factor in adherence.
It has been clearly demonstrated that SLIT is cost-
effective in terms of reducing the use of symptomatic drugs, 
and becomes even more cost-effective when SLIT can be 
stopped after an adequate treatment duration and continues 
to be effective in controlling allergic symptoms.21 However, 
it is understandable that patients absorbing the cost of SLIT 
may not be convinced on this issue, even after adequate 
information is given.
In conclusion, the results of this survey suggest that there 
is still room for improving the extent of patient adherence 
with SLIT, and that patient understanding of the specialists’ 
perception, beliefs, and attitudes might be a fruitful advance. 
In particular, the perception of some aspects of treatment 
appears to some extent to be unrelated to the current sci-
entific knowledge about SLIT, and may be improved by 
more complete information being provided. Moreover, the 
allergists’ preference for telephone contact is another factor 
potentially able to improve adherence to treatment, as has 
been demonstrated in diabetic patients.22
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